BioAge Labs, Inc. (BIOA)
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
BioAge Labs NASDAQ: BIOA executives used a fireside chat at the Jefferies 2026 Global Healthcare Conference to outline the company's plans for BGE-102, its lead NLRP3 inhibitor, with near-term readouts expected in cardiovascular risk and diabetic macular edema.
BioAge Labs, Inc. (BIOA) Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease Transcript
BioAge Labs, Inc. (BIOA) Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease Transcript
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials
BioAge Labs NASDAQ: BIOA used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing across cardiovascular and retinal disease. Management highlighted phase I clinical results, plans for near-term proof-of-concept studies, and the rationale for pursuing inflammation as a therapeutic target.
BioAge Labs Touts Phase 1 BGE-102 Data, Citing 86% hs-CRP Drop and Clean Safety Profile
BioAge Labs (NASDAQ: BIOA) executives outlined phase I results for its oral, brain-penetrant NLRP3 inhibitor BGE-102, highlighting what the company characterized as deep reductions in inflammatory biomarkers-particularly high-sensitivity C-reactive protein (hs-CRP)-alongside a tolerability profile management said supports accelerated development into phase II studies. Phase I program design and key objectives Chief Medical Officer Dr. Paul Rubin
BioAge Labs, Inc. (BIOA) Discusses Phase I Results and Development Plans for BGE-102 NLRP3 Inhibitor Transcript
BioAge Labs, Inc. (BIOA) Discusses Phase I Results and Development Plans for BGE-102 NLRP3 Inhibitor Transcript
BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans
BioAge Labs Inc (NASDAQ:BIOA) shares are up on Tuesday after the company reported positive Phase 1 data for BGE-102, an oral NLRP3 inhibitor.
Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know
The mean of analysts' price targets for BioAge Labs, Inc. (BIOA) points to an 183.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BioAge Labs: Oral NLRP3 Inhibitor Could Establish PoC In CV This Year
BioAge Labs is rated Buy, leveraging strong early data for BGE-102, a novel oral NLRP3 inhibitor targeting cardiovascular and ophthalmology markets. BGE-102 achieved 86% hsCRP reduction and favorable safety in Phase 1, positioning BIOA for a pivotal Phase 2a trial in 2H 2026. BIOA holds ~$285M in cash post-raise, funding operations through 2029 and supporting multiple clinical milestones, including new obesity and ophthalmology candidates.
BIOA Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against BioAge Labs, Inc. (BIOA)
RADNOR, PA - February 28, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against BioAge Labs, Inc. (BioAge) (NASDAQ: BIOA) on behalf of those who purchased stock pursuant and/or traceable to BioAge's registration statement for its initial public offering (IPO) held on or about September 26, 2024 (the Class Period). The lead plaintiff deadline is March 10, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: aAdsList.push('Article'); aAdsListSize.push([300, 250]); aAdsListCA.push(null); If you suffered BioAge losses, you may CLICK HERE or copy and paste the following link in your browser: Click Here can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected] . DEFENDANTS ALLEGED MISCONDUCT: The complaint alleges that, in the registration statement and prospectus issued in connection with BioAges IPO, Defendants made false and/or misleading statements and/or failed to disclose information pertinent to investors concerning BioAges STRIDES Phase 2 trial for azelaprag. Specifically, Defendants misrepresented and/or failed to disclose: (1) the potential for liver transaminitis in any of its previous clinical STRIDES Phase 1 trials and various preclinical tox studies; (2) that there were no safety concerns and that BioAge expected top line results and to meet its primary endpoint goals in connection with its STRIDES clinical trial; and (3) as a result, Defendants statements about the companys business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. THE LEAD PLAINTIFF PROCESS: BioAge investors may, no later than March 10, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages BioAge investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: Click Here KESSLER TOPAZ MELTZER & CHECK, LLP: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com . CONTACT: Kessler Topaz Meltzer & Check, LLPJonathan Naji, Esq. (484) 270-1453 280 King of Prussia RoadRadnor, PA 19087 [email protected] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. View the original release on www.newmediawire.comCopyright 2025 JCN Newswire . All rights reserved.© Japan Corporate News, source JCN Press Releases
BioAge Labs, Inc. Class Action: Levi & Korsinsky Reminds BioAge Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - BIOA
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Shareholders of BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
BioAge Labs, Inc. Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the BIOA Class Action
SAN DIEGO, CA / ACCESSWIRE / January 15, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all shareholders who purchased stock pursuant and/or traceable to the BioAge Labs, Inc. (NASDAQ:BIOA) registration statement for the initial public offering (IPO) held on September 26, 2024. BioAge claims it is a "clinical stage biopharmaceutical company" that develops therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging.
